TAG and the Global TB CAB have a long history of advocating for the uptake of new health innovations, influencing global and national decision-making, and supporting policy translation. In March 2026, the World Health Organization (WHO) recommended a new class of tests — near point-of-care (NPOC) molecular tests — that offer faster, more decentralized, cheaper, and more accessible TB diagnosis
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.
This year revealed how far this administration is willing to go in undermining public health. The White House refused to recognize World AIDS Day. Global and domestic HIV, TB, and HCV programs were directly threatened, and many were terminated. Senior CDC leaders resigned rather than carry out political firings or oversee the degradation of national vaccine guidance. And in August, a vigilante encouraged by political rhetoric fired nearly 500 rounds into the CDC campus in Atlanta and killed a police officer. The President has still not publicly acknowledged the attack.
TAG signed onto this letter sponsored by the HIV Legal Network to Canadian Prime Minister Mark Carney about the importance of strong investments in health and community systems as they reinforce global health security, which in turn keeps everyone safe.
In March 2025, the National Institute of Allergy and Infectious Diseases (NIAID) began soliciting comments on the future of the four Division of AIDS (DAIDS)-sponsored HIV clinical research networks: ACTG, IMPAACT, HPTN, and HVTN.
TAG sent this comment to the Centers for Disease Control and Prevention (CDC) September 2025 meeting on how to leverage same-day diagnosis and treatment for hepatitis C.
TAG letter urging the Advisory Committee on Immunization Practices (ACIP) to maintain the recommendation of a universal hepatitis B virus (HBV) birth dose vaccine in the United States.
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.
Treatment Action Group (TAG) is issuing an urgent call to protect the integrity of biomedical research and public health.
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP).